Member Info for Yorkshirepragma

https://mologic.co.uk/avacta-and-mologic-announce-commercial-partnership/

As if anyone needed reminding....

GLA

Epping, well said. USA profile for LFTs will lead to ‘ interesting’ company reviews for this area.
GLA

Potentially shortest friends... desperation

APAC interest significant ,it seems in testing...several articles circulating
GLA

https://www.abc.net.au/news/2021-07-04/singapore-considers-a-radical-new-approach-to-covid-19/100256272

Wyndrum ,good analysis, and also the ‘best test
‘ is now out in the market .
Could change rapidly as the ‘ shorters’ will know.
GLA

U.K. represents <5% ca. of pot.market. AS has set out what is a fast developing broad positive position.
GLA

Whaler serving ‘bratwurst special ‘ from tonight..eh up wunderbar…

For the naysayers….market
https://ourworldindata.org/grapher/daily-covid-19-tests-smoothed-7-day

And Orient Gene only good for clinical use...

That’s rerate..lapologies

A change in S upport ( from PR and noted quality ) via WW use, will likely relate this share.
stateside preferable ,but APAC would do.
Valuation on forward pot. rev. Rather than’ bread and butter’ stock review leads to a higher outcome.
GLA

https://seekingalpha.com/article/4240702-biotech-bonanza-mergers-and-acquisitions-theme

Sadly inside track says This this would require much cash and several years to bring to life......great pity this Avenue not being explored.
GLA

Just checked UK to France & return testing costs @£200. Head....who says there’s no £ in this.!?

If you read the Gov. Protocol it’s a satisfactory cohort...

.

https://www.defense.gov/Newsroom/Releases/Release/Article/2454163/dod-awards-48-million-indefinite-deliveryindefinite-quantity-to-a-calibre-scien/

Maria, and ‘word is‘ that come end Summer/ Aug the Innova brand will be dumped to avoid the embarrassment

Cant Cc to post, but take a look if you want an insight into the ‘messy’ process (polite), and if you overlay AS recent aside comment on slow nature of gov. links, the waters clear...
GLA

54...GSK could still do a deal though...keen on cancer strategies...GLA
https://www.ft.com/content/a8edb8fb-4ab6-49ed-8c81-326c862d75ec